Historical Development

2011

Founding year, oriented to a comprehensive CRO preparation centralab crossing preclinical and whole-process clinical services

2012

Build up a Bioanalysis Lab of more than 3000 square meters in Medical Town of Liaoning

2013

• Headquartered in Beijing
• The Bioanalysis Lab was CNAS certified
• Selected as one of “Gold Seed Enterprises” of Zhongguancun Science and Technology Garden

2014

• Awarded the title of “High-tech Enterprise”
• Set up an internship base with Shenyang Pharmaceutical University

2015

After “722”, undertook a large number of BE/PK projects successively

2016

• Service project “"Ciprofloxacin" is the first project having passed verification
• In the same year, built up nearly 10 Clinical Research Centers in such areas as Beijing, Jiangsu, Hainan, Hebei, Shenyang, Henan and Liaoning
• Built up IVIVC Institute

2017

• Entered into strategic partnership agreements with “Hengrui, Yangtze River Pharmaceutical Group, GSK, MERCK, Disha, Qilu and Lunan” successively
• Undertake the clinical trial service for drugs on nervous system
• Develop cerebroma Car-T project
• More than 100 customers served

2018

• Be a member unit of “China Association of Rehabilitation Technology Transformation & Promotion (CARTTP)”
• Selected as a strategic partner of “Community of Common Destiny in Medicine”
• Be a “Full Corporation Partner” of Fudan Fuhua
• Have an in-depth cooperation with Beijing Xuanwu Hospital
• Develop ovarian cancer Car-T project
• Develop overall clinical trial service

2019

• Develop the project service of endogenous medicinal substances
• Undertake the drug clinical trial of the first type of new drug and bio-pharmaceuticals
• Undertake several drug clinical trials of narrow window drugs and high variation drug
• Develop multicenter trial service, nearly 40 hospitals

2020

• Undertake the project service for hepatopathy, with more than 15 single multicenter trials
• Be a director unit of CRO Branch of China Quality Association for Pharmaceuticals
• Step into the field of nuclear medicine, having reached cooperation with China National Nuclear Corporation and provided multicenter clinical trial service for F18 NaF project
• Step into the field of reproductive medicine, undertake embryo selection project
• Develop several businesses of Sino-US of Investigational New Drug Application (IND)

2021

Expand the market in Eastern China and set up branches in Shanghai and Hangzhou